Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.

TSX:TH - Post by User

Theratechnologies Inc > Addressable market

<< Previous

Bullboard Posts

Next >>

Post by scarlet1967on May 04, 2023 9:08am

206 Views

Post# 35429566

Addressable market

As per company's CP.

Over 800 k patient are currently treated with ART in the US some 3.6 percent (over 30 k) of treated patients are heavily treated. Addressable market estimates at $240m. The drugs currently used for HTE cohorts failing their regimen are ibalizumab, Rukobia and Sunlenca often together.

This data gives an incentive for doctors and patients to include ibalizumab in that addressable market. The question is whether they can convince doctors to change the heavily treated patient's regimen to much more efficient ibalizumab before the viral failure based on this real world data?

<< Previous

Bullboard Posts

Next >>

How a junior advances one of the largest undeveloped diamond projects